Skip to main content
Features
Assistant
AI grounded in research
Search
Full-text citation search
Collections
Organize and monitor papers
All Features →
Integrations
MCP
Connect AI agents to Scite
API
Programmatic data access
Holdings
Full-text via your library
Zotero Plugin
Citation data in Zotero
Browser Extension
Citation badges anywhere
All Integrations →
Data
Rankings
Pricing
Log In
Start Free Trial
Features
Assistant
AI grounded in research
Search
Full-text citation search
Collections
Organize and monitor papers
All Features →
Integrations
MCP
Connect AI agents to Scite
API
Programmatic data access
Holdings
Full-text via your library
Zotero Plugin
Citation data in Zotero
Browser Extension
Citation badges anywhere
All Integrations →
Data
Rankings
Pricing
Log In
Start Free Trial
Scott Randall Plotkin
Sign up to set email alerts
809
Publications
12,336
Citation Statements Received
16,844
Citation Statements Given
How they've been cited
17,180
397
11,868
71
How they cite others
21,000
403
16,359
82
Affiliations
Massachusetts General Hospital
,
Harvard University
Publications
Order By: Most citations
AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma Patients
Batchelor
1
,
Sorensen
2
,
di Tomaso
3
et al.
2007
Cancer Cell
Abstract
Show
1,760
57
1,277
14
Get article
Add to collection
Cite
Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation
Legius
1
,
Messiaen
2
,
Wolkenstein
3
et al.
2021
Genetics in Medicine
Abstract
Show
908
8
537
0
Get article
Add to collection
Cite
Use of Video to Facilitate End-of-Life Discussions With Patients With Cancer: A Randomized Controlled Trial
El-Jawahri
1
,
Podgurski
2
,
Eichler
3
et al.
2010
JCO
Abstract
Show
261
9
359
1
Get article
Add to collection
Cite
Hearing Improvement after Bevacizumab in Patients with Neurofibromatosis Type 2
Plotkin
1
,
Stemmer-Rachamimov
2
,
Barker
3
et al.
2009
N Engl J Med
Abstract
Show
534
10
340
2
Get article
Add to collection
Cite
Phase II Study of Cediranib, an Oral Pan–Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma
Batchelor
1
,
Duda
2
,
di Tomaso
3
et al.
2010
JCO
Abstract
Show
515
23
331
1
Get article
Add to collection
Cite
Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation
Batchelor
1
,
Gerstner
2
,
Emblem
3
et al.
2013
Proc. Natl. Acad. Sci. U.S.A.
Abstract
Show
355
15
327
2
Get article
Add to collection
Cite
Diagnostic criteria for schwannomatosis
MacCollin
1
,
Chiocca
2
,
Evans
3
et al.
2005
Neurology
Abstract
Show
422
4
307
0
Get article
Add to collection
Cite
Randomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma Multiforme
Reardon
1
,
Fink
2
,
Mikkelsen
3
et al.
2008
JCO
Abstract
Show
480
4
308
0
Get article
Add to collection
Cite
1
2
3